Status:
WITHDRAWN
Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly
Lead Sponsor:
University of Copenhagen
Collaborating Sponsors:
Bispebjerg Hospital
Elysium Health
Conditions:
COVID
Eligibility:
All Genders
70+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate whether nicotinamide riboside supplementation can attenuate the severity of SARS-CoV-2 infections in elderly patients. A major event in aging is the loss o...
Detailed Description
Currently the number of SARS-CoV-2 positive patients are increasing worldwide and healthcare systems are attempting to cope with the massive pressure that this pandemic results in. Given the highly in...
Eligibility Criteria
Inclusion
- Written informed consent
- Age 70 or older, inclusive at the time of diagnosis.
- Body mass index between 18-40 kg/m2 (both inclusive) and weight ≥ 40 kg at enrolment.
- A diagnosis of Covid-19.
Exclusion
- Need for oxygen therapy.
- Ongoing severe acute respiratory syndrome.
- Cancer diagnosis within last 5 years.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Concurrent enrollment in another clinical study involving an investigational treatment.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04407390
Start Date
June 1 2020
End Date
May 1 2022
Last Update
September 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bispebjerg Hospital
Copenhagen NV, Denmark, 2400